Effect of Modified Guifu Dihuang Wan on Quality of Life of Patients with Coronary Heart Disease After PCI and Evaluation on Medication Safety
10.13422/j.cnki.syfjx.20190118
- VernacularTitle: 桂附地黄丸加减对冠心病PCI术后患者生活质量的影响及用药安全性评价
- Author:
Wen-jin HE
1
;
Shi YANG
1
;
Fan LIU
1
;
Ying LI
1
;
Jia YUAN
1
Author Information
1. Chongqing Traditional Chinese Medicine Hospital, Chongqing 400011, China
- Publication Type:Research Article
- Keywords:
modified Guifu Dihuang Wan;
percutaneous coronary intervention (PCI);
quality of life;
safety
- From:
Chinese Journal of Experimental Traditional Medical Formulae
2019;25(4):122-127
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To explore effect of modified Guifu Dihuang Wan (Wenshen Huoxue Fang) on life quality in patients with coronary hear disease (CHD) after percutaneous coronary intervention (PCI) and evaluate the safety of its clinical use. Method: The 147 postoperative patients with PCI in Chongqing Traditional Chinese Medicine Hospital cardiology outpatient and the inpatient departments between June 2017 to May 2018 were selected and randomly divided into the treatment group and control group by random even and odd number. The patients in control group took the basic treatment (western medicine), and the patients in the treatment group additionally received modified Guifu Dihuang Wan based on the treatment in control group, with a course of 4 weeks in both groups. Minnesota Living with Heart Failure Questionnaire (MLHFQ) total score, 6 minutes walk test (6 mWT), Seattle Angina Scale (SAQ) score, and traditional Chinese medicine(TCM) syndrome score were recorded and compared between two groups before and after treatment; their cardiac function was evaluated and adverse reactions were observed to assess the drug safety and quality of life after PCI. Result: The MLHFQ scores in treatment group after treatment were significantly lower than those before treatment and those in control groups after treatment (P<0.01); 6 mWT walking distance was significantly increased (P<0.01); SAQ scores were improved significantly (P<0.01); TCM syndrome score was reduced significantly (P<0.01); left ventricular ejective fraction (LVEF) and late diastolic/late diastolic maximal blood flow velocity (E/A) in treatment group were also improved after treatment (P<0.05). Conclusion: On the basis of conventional western medicine therapy, the modified Guifu Dihuang Wan can effectively improve the physical strength, mood, TCM symptoms, relieve angina pectoris, and enhance cardiac function with no adverse reactions in PCI postoperative patients. It can achieve the purpose of improving quality of life in postoperative patients, worthy of promotion.
